CG
EIGR

Cutler Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cutler Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33
Closed – – 3927
2023
Q4 		$0 Hold
33
– – ﹤0.01% 4542
2023
Q3 		$0 Hold
33
– – ﹤0.01% 4468
2023
Q2 		$0 Hold
33
– – ﹤0.01% 4349
2023
Q1 		$0 Sell
33
-4
-11% -$186 ﹤0.01% 4946
2022
Q4 		$1K Buy
37
+7
+23% +$841 ﹤0.01% 4231
2022
Q3 		$6K Buy
+30
New +$7.38K ﹤0.01% 3577
2020
Q4 		– Sell
-103
Closed -$29.5K – 5663
2020
Q3 		$25K Buy
+103
New +$32K ﹤0.01% 2296
2017
Q2 		– Sell
-38
Closed -$12K – 7270
2017
Q1 		$12K Hold
38
– – ﹤0.01% 3893
2016
Q4 		$13K Hold
38
– – ﹤0.01% 3934
2016
Q3 		$15K Sell
38
-2
-5% -$1.02K ﹤0.01% 3748
2016
Q2 		$23K Hold
40
– – ﹤0.01% 3222
2016
Q1 		$19K Hold
40
– – ﹤0.01% 3359
2015
Q4 		$26K Buy
+40
New +$22.6K ﹤0.01% 3154

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Cutler Group's EIGR Position: Q1 2024 in Review

Cutler Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 33 shares.

Cutler Group first reported a position in EIGR in Q4 2015 and held it in 13 quarters. The position peaked at $26K in Q4 2015. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Cutler Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 33 Eiger BioPharmaceuticals, Inc. shares in Q1 2024.
  • Cutler Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2015 and held it in 13 quarters.
  • Cutler Group's Eiger BioPharmaceuticals, Inc. position peaked at $26K in Q4 2015.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.